Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Mark A. Atkinson
University of Florida
513Publications
82H-index
25.9kCitations
Publications 513
Newest
Published in Nature Communications 11.88
Jordan T. Russell2
Estimated H-index: 2
(UF: University of Florida),
Luiz Fernando Wurdig Roesch21
Estimated H-index: 21
(Universidade Federal do Pampa)
+ -3 AuthorsJohnny Ludvigsson61
Estimated H-index: 61
(Boston Children's Hospital)
Susceptibility to many human autoimmune diseases is under strong genetic control by class II human leukocyte antigen (HLA) allele combinations. These genes remain by far the greatest risk factors in the development of type 1 diabetes and celiac disease. Despite this, little is known about HLA influences on the composition of the human gut microbiome, a potential source of environmental influence on disease. Here, using a general population cohort from the All Babies in Southeast Sweden study, we...
Published on Mar 12, 2019in Scientific Reports 4.01
Jing Yong6
Estimated H-index: 6
(UCLA: University of California, Los Angeles),
Jide Tian29
Estimated H-index: 29
(UCLA: University of California, Los Angeles)
+ 4 AuthorsDaniel L. Kaufman32
Estimated H-index: 32
(UCLA: University of California, Los Angeles)
There has been considerable debate as to whether obesity can act as an accelerator of type 1 diabetes (T1D). We assessed this possibility using transgenic mice (MIP-TF mice) whose s-cells express enhanced green fluorescent protein (EGFP). Infecting these mice with EGFP-expressing murine herpes virus-68 (MHV68-EGFP) caused occasional transient elevation in their blood glucose, peri-insulitis, and Th1 responses to EGFP which did not spread to other s-cell antigens. We hypothesized that obesity-rel...
Published in The Lancet 59.10
Julio Rosenstock112
Estimated H-index: 112
,
Paul Zimmet108
Estimated H-index: 108
(Monash University)
+ -3 AuthorsK. George M.M. Alberti (Imperial College London)
Published on Jun 3, 2019in Diabetes Care 15.27
Maria J. Redondo20
Estimated H-index: 20
(BCM: Baylor College of Medicine),
Carmella Evans-Molina21
Estimated H-index: 21
+ 2 AuthorsJay M. Sosenko (UM: University of Miami)
Current efforts to prevent progression from islet autoimmunity to type 1 diabetes largely focus on immunomodulatory approaches. However, emerging data suggest that the development of diabetes in islet autoantibody–positive individuals may also involve factors such as obesity and genetic variants associated with type 2 diabetes, and the influence of these factors increases with age at diagnosis. Although these factors have been linked with metabolic outcomes, particularly through their impact on ...
Published on Jun 6, 2019in The Lancet Diabetes & Endocrinology 24.54
Sylvia Kehlenbrink9
Estimated H-index: 9
(Brigham and Women's Hospital),
Lindsay M. Jaacks13
Estimated H-index: 13
(Harvard University)
+ 61 AuthorsPhilippa Boulle4
Estimated H-index: 4
Published on May 24, 2019in Diabetes 7.20
Klaus H. Kaestner85
Estimated H-index: 85
(UPenn: University of Pennsylvania),
Alvin C. Powers49
Estimated H-index: 49
(Vandy: Vanderbilt University)
+ 1 AuthorsMark A. Atkinson82
Estimated H-index: 82
(UF: University of Florida)
Type 1 diabetes risk can reliably be predicted by markers of autoimmunity, but approaches to prevent or modify the underlying disease process are needed. We posit this void fundamentally results from a limited understanding of immune-islet cell interactions within the pancreas and relevant immune organs, contributions of β-cells to their own demise, and epigenetic predispositions affecting both immune and islet cells. Because biopsy of the human pancreas and pancreatic lymph nodes carries risk a...
Published on Jun 1, 2019in Diabetes 7.20
Michael Haller33
Estimated H-index: 33
(UF: University of Florida),
Michael Haller (UF: University of Florida)+ 21 AuthorsSusan Geyer48
Estimated H-index: 48
(USF: University of South Florida)
A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA 1c for 1 year in new-onset type 1 diabetes. Subjects ( N = 89) were randomized to 1 ) ATG and pegylated granulocyte colony-stimulating factor (GCSF), 2 ) ATG alone, or 3 ) placebo. Herein, we report 2-year area under the curve (AUC) C-peptide and HbA...
Published on Jun 1, 2019in Diabetologia 7.11
Jessica L. Dunne5
Estimated H-index: 5
(JDRF),
Sarah J. Richardson24
Estimated H-index: 24
(University of Exeter)
+ 7 AuthorsAlberto Pugliese34
Estimated H-index: 34
(UM: University of Miami)
12345678910